Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 24, 2007 Brian Lawler	Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.
The Motley Fool July 21, 2005 Tom Taulli	Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.
The Motley Fool January 29, 2007 Brian Lawler	No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool July 12, 2004 Ben McClure	Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.
The Motley Fool October 24, 2006 Brian Lawler	Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
The Motley Fool December 16, 2003 Rick Aristotle Munarriz	Amgen's Cannibalistic Ways Amgen's prospects look good, and it is planning a large share buyback.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool July 21, 2006 Brian Lawler	Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note.
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool March 16, 2006 Charly Travers	Stock Madness 2006: Health Care and Hem-Stitching In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2006." This powerhouse team has long-term potential. Jo-Ann Stores... Amgen... etc.
The Motley Fool October 25, 2011 Brian Orelli	Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool January 12, 2007 Brian Lawler	Genentech on a Roll 2006 was a great year for the world's largest biotech firm. Investors should follow Genentech closely, as the company's a bellwether for the rest of the biopharmaceutical sector.
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool November 16, 2004 Charly Travers	Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
The Motley Fool December 20, 2011 Brian Orelli	If You Can't Beat 'Em, Join 'Em: Amgen Goes Generic Biosimilars are coming -- might as well get a piece of the action.
The Motley Fool November 9, 2006 Karl Thiel	The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note.
The Motley Fool May 29, 2007 Brian Lawler	Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Red and White Results at Amgen At current levels, this biotech titan could be worth a further look from investors.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool March 29, 2004 Jeff Hwang	Amgen Deals Again Two years after acquiring Immunex, Amgen takes Tularik.
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool March 16, 2006 Rich Smith	Stock Madness 2006: Tech Titan Triumphant? In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2006." With Cisco at center, can this diverse team score big? Cisco... Plum Creek... American Eagle... etc.
The Motley Fool April 25, 2011 Brian Orelli	Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool February 23, 2005 Brian Gorman	Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies.
The Motley Fool December 20, 2011 Luke Timmerman	Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars?
The Motley Fool June 7, 2007 Brian Lawler	Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline.
Chemistry World October 28, 2014 Phillip Broadwith	Amgen stacks up additional job cuts US biotech heavyweight Amgen is to cut an extra 600 -- 1100 jobs by the end of 2015, on top of the 2900 the company earmarked for the chop in August.
The Motley Fool August 11, 2010 Brian Orelli	Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough.
The Motley Fool October 3, 2008 Brian Orelli	Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche.
The Motley Fool July 28, 2009 Brian Orelli	Amgen Secures Its Future Earnings and a marketing partnership -- oh my.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool May 27, 2009 Brian Orelli	A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.
The Motley Fool January 25, 2008 Brian Lawler	Amgen: Punched Out or Still Fighting? Amgen manages to pull off a 3.5% increase in revenue for 2007, even with sales of its anemia franchise drugs Aranesp and Epogen down a combined 17% year over year in the fourth quarter.
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool October 21, 2004 W.D. Crotty	One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings.
BusinessWeek March 22, 2004 Arlene Weintraub	Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool October 7, 2004 Charly Travers	Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.